← The library
Larazotide
researchGI/Bone/OtherEvidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
0
PurposeGI / Bone / Other
MechanismTight-junction regulator studied for intestinal permeability in coeliac disease
EffectsStudied for gut barrier integrity; failed its Phase 3 endpoint in coeliac disease in 2022
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Batches on file1
80 mgno purity figure
Cautions & interactions
Not FDA-approved; avoid self-administration; unverified sourcing and purity
No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.
CV 0 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.